GlassScriptPhysician profile
Sarfraz Aly
NPI 1972766327
$35,327.35
in general payments reported to CMS, 2019-2025
38 companies · $23K in 2025
The $23K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,662 · 2021: $976 · 2022: $1,459 · 2023: $1,092 · 2024: $5,956 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $4,738 · Travel and Lodging: $702 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,250.00 |
| Food and Beverage | $4,737.55 |
| Travel and Lodging | $701.54 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,668.51 | 2021-2025 | Dalvance, Avycaz |
| Smith+Nephew, INC. | $3,096.43 | 2019-2025 | Grafix Pl, Grafix, Stravix Pl |
| Mimedx Group, INC. | $684.78 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $554.27 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Allergan, INC. | $454.50 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $307.44 | 2019-2025 | Nuzyra |
| Boston Scientific Corporation | $290.26 | 2022-2024 | Ekosonic |
| Gilead Sciences, INC. | $270.51 | 2020-2025 | |
| Reddress USA, INC. | $241.88 | 2024 | |
| Ets Wound Care LLC | $236.77 | 2024 | Mirragen Advanced Wound Matrix |
| Tetraphase Pharmaceuticals, INC. | $213.05 | 2019-2020 | |
| Hartmann USA, INC. | $205.47 | 2020-2022 | |
| Silk Road Medical, INC. | $182.65 | 2020 | |
| Viiv Healthcare Company | $169.00 | 2019-2022 | |
| Urgo Medical North America, LLC | $162.58 | 2024-2025 | Urgoclean Ag |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $162.14 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Melinta Therapeutics, LLC | $161.35 | 2019-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Insmed, INC. | $150.29 | 2019-2025 | Arikayce |
| Organogenesis INC. | $133.16 | 2021-2025 | Via Matrix |
| Osiris Therapeutics INC. | $131.20 | 2019 | |
| Inari Medical, INC. | $125.33 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shionogi INC | $111.91 | 2020-2023 | Fetroja |
| Lilly USA, LLC | $76.36 | 2022 | |
| Misonix INC | $73.27 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $57.66 | 2020-2022 | |
| Convatec INC. | $53.41 | 2020-2021 | |
| Musculoskeletal Transplant Foundation INC. | $52.98 | 2019 | |
| La Jolla Pharmaceutical Company | $51.14 | 2024-2025 | Zevtera, Xerava |
| Kci USA, INC. | $45.44 | 2021-2023 | Activ.A.C., Promogran, 3m Cavilon |
| Mayne Pharma Commercial LLC | $40.19 | 2020-2021 | |
| Reapplix INC. | $26.48 | 2021 | |
| Solventum Corporation | $25.98 | 2025 | Activ.A.C. |
| Astrazeneca Pharmaceuticals LP | $22.44 | 2022 | |
| Janssen Biotech, INC. | $22.14 | 2020 | |
| Dynavax Technologies Corporation | $20.78 | 2019 | |
| Aroa Biosurgery Incorporated | $18.69 | 2023 | |
| Tactile Systems Technology INC | $14.30 | 2020 | |
| Abbott Laboratories | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarfraz Aly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.